Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients

Stroke

Volumn 45, Issue 5, 2014, Pages 1429-1436

  Sirimarco, Gaia ^a,b   Labreuche, Julien ^a,c   Bruckert, Eric ^d   Goldstein, Larry B ^e   Fox, Kim M ^f   Rothwell, Peter M ^g   Amarenco, Pierre ^a,b   Bousser, Marie Germaine ^h   Chamorro, Angel ^h   Ford, Ian ^h   Fisher, Marc ^h   Hennerici, Michael G ^h   Mattle, Heinrich ^h   Callahan, Fred ^h   Sillesen, Henrik ^h   Welch, K Michael A ^h   Zivin, Justin A ^h  

^a INSERM   (France)

^b BICHAT HOSPITAL   (France)

^c UNIV LILLE   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e DURHAM VA MEDICAL CENTER   (United States)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

^g JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^h NONE

Author keywords

Cardiovascular diseases; HMG CoA reductase inhibitors; Lipids; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TERUTROBAN; TRIACYLGLYCEROL;

AGED; ARTICLE; ATHEROGENIC DYSLIPIDEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK REDUCTION; SENSITIVITY ANALYSIS; TRANSIENT ISCHEMIC ATTACK;

CARDIOVASCULAR DISEASES; HMG-COA REDUCTASE INHIBITORS; LIPIDS; STROKE;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; COMORBIDITY; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; STROKE; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84899970979     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.004229     Document Type: Article

References (41)

1. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453-463.
2. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102(10 suppl):1K-34K.
3. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126:314-345.
4. Lim S, Park YM, Sakuma I, Koh KK. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol. Int J Cardiol. 2013;166:8-14.
5. Fiévet C, Staels B. Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr Opin Lipidol. 2009; 20:505-511.
6. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, et al; Asia Pacific Cohort Studies Collaboration. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110:2678-2686.
7. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
8. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis. 2008;196:489-496.
9. Labreuche J, Touboul PJ, Amarenco P. Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies. Atherosclerosis. 2009;203:331-345.
10. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124(suppl):S11-S20.
11. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-714.
12. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004;109:42-46.
13. Bruckert E, Baccara-Dinet M, Eschwege E. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey. Diabet Med. 2007;24:388-391.
14. Maron DJ. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol. 2000;86(12A):11L-14L.
15. Li C, Ford ES, Tsai J, Zhao G, Balluz LS, Gidding SS. Serum non-high-density lipoprotein cholesterol concentration and risk of death from cardiovascular diseases among U.S. adults with diagnosed diabetes: the Third National Health and Nutrition Examination Survey linked mortality study. Cardiovasc Diabetol. 2011;10:46.
16. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634-1639.
17. Chaudhary R, Likidlilid A, Peerapatdit T, Tresukosol D, Srisuma S, Ratanamaneechat S, et al. Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol. 2012;11:36.
18. Chiang JK, Lai NS, Chang JK, Koo M. Predicting insulin resistance using the triglyceride-to-high-density lipoprotein cholesterol ratio in Taiwanese adults. Cardiovasc Diabetol. 2011;10:93.
19. Hopkins PN, Wu LL, Hunt SC, Brinton EA. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol. 2005;45:1003-1012.
20. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al; FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
21. Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
22. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875-1884.
23. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2011;57:267-272.
24. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363:692-694, author reply 694.
25. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, et al. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovasc Dis. 2009;27:509-518.
26. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, et al; PERFORM Study Investigators. The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. Cerebrovasc Dis. 2009;27:608-613.
27. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, et al; PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet. 2011;377:2013-2022.
28. Amarenco P, Bogousslavsky J, Callahan AS, Goldstein L, Hennerici M, Sillsen H, et al; SPARCL Investigators. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis. 2003;16:389-395.
29. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
30. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
31. Ghali WA, Quan H, Brant R, van Melle G, Norris CM, Faris PD, et al; APPROACH (Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease) Investigators. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA. 2001;286:1494-1497.
32. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin. 2005;21:1927-1934.
33. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
34. Assmann G, Schulte H, Cullen P, Seedorf U. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur J Clin Invest. 2007;37:925-932.
35. Assmann G, Schulte H, Seedorf U. Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study. Int J Obes (Lond). 2008;32(suppl 2):S11-S16.
36. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450-458.
37. Assmann G. Dyslipidaemia and global cardiovascular risk: clinical issues. Eur Heart J. 2006;8:F40-F46.
38. Arca M, Montali A, Valiante S, Campagna F, Pigna G, Paoletti V, et al. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. Am J Cardiol. 2007;100:1511-1516.
39. Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol. 2012;11:125.
40. Tenenbaum A, Medvedofsky D, Fisman EZ, Bubyr L, Matetzky S, Tanne D, et al. Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data. PLoS One. 2012;7:e35298.
41. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309-316.